Pharma Penny Stock Under Rs 50 in Green After Signing an MoU with Indian Navy (INS Kalinga)
The company has a market cap of over Rs 1,200 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
Today, shares of Sigachi Industries Ltd gained 0.74 per cent to Rs 38.29 per share from its previous closing of Rs 38.01 per share. The company has a market cap of over Rs 1,200 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
Sigachi Industries Limited has entered into a Memorandum of Understanding (MoU) with the Indian Navy (INS Kalinga) to jointly promote "Healthy Living" through the "Vizag Navy Marathon Promo cum Conditioning Programme." This initiative will feature structured fitness events, training sessions, and community engagement held on the second Sunday of each month from March 2025 to October 2025 in Visakhapatnam. The partnership, formalized by Amit Raj Sinha, Managing Director & CEO of Sigachi Industries, and Cmde SP Patel, Commanding Officer of INS Kalinga, on March 10, 2025, signifies a long-term commitment to enhancing public health and wellness across the region.
The primary goal of this collaboration is to empower individuals to embrace healthier lifestyles and increase participation in public health initiatives. By leveraging the combined resources and influence of Sigachi Industries and the Indian Navy, the program aims to foster a culture of health and wellness within the community. Sigachi Industries is dedicated to driving socially responsible initiatives that align with its mission of advancing health, wellness, and holistic well-being.
Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, stated, “We are excited to join hands with INS Kalinga of the Indian Navy to make a difference in Vizag’s fitness journey. This programme will not only promote healthy living but also serve as a platform to bring people together for creating a healthier, happier, and joyful world.”
Commenting on this development, Cmde SP Patel, Commanding Officer of INS Kalinga, said, “INS Kalinga is thrilled to collaborate with Sigachi Industries on this transformative initiative. The Vizag Navy Marathon Promo cum Conditioning Programme is about much more than physical fitness; it’s about cultivating a long-term commitment to health, teamwork, and perseverance within the local community.”
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialize in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilizing advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q3FY25) and nine-month results (9MFY24). According to quarterly results, revenue increased by 26 per cent to Rs 139.42 crore, EBITDA increased by 45 per cent to Rs 35.19 crore and consolidated net profit increased by 33 per cent to Rs 21.35 crore in Q3FY25 compared to Q3FY24. In its nine-month results, revenue increased by 22 per cent to Rs 360.03 crore, EBITDA increased by 39 per cent to Rs 89.75 crore and consolidated PAT increased by 33 per cent to Rs 56.29 crore in 9MFY25 compared to 9MFY24.
From Rs 34.51 per share (52-week low) to Rs 38.29 per share, the stock is up by 11 per cent. Investors should keep an eye on this small-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.